Trustmark National Bank Trust Department Buys New Position in Hologic, Inc. (NASDAQ:HOLX)

Trustmark National Bank Trust Department purchased a new position in Hologic, Inc. (NASDAQ:HOLX) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 2,619 shares of the medical equipment provider’s stock, valued at approximately $213,000.

A number of other institutional investors have also recently modified their holdings of HOLX. Seven Eight Capital LP lifted its position in shares of Hologic by 35.3% during the 1st quarter. Seven Eight Capital LP now owns 4,169 shares of the medical equipment provider’s stock valued at $325,000 after buying an additional 1,088 shares in the last quarter. Bessemer Group Inc. lifted its holdings in shares of Hologic by 8.0% in the 1st quarter. Bessemer Group Inc. now owns 10,892 shares of the medical equipment provider’s stock worth $848,000 after buying an additional 809 shares during the period. Shell Asset Management Co. lifted its holdings in shares of Hologic by 68.6% in the 1st quarter. Shell Asset Management Co. now owns 10,517 shares of the medical equipment provider’s stock worth $820,000 after buying an additional 4,279 shares during the period. Canada Pension Plan Investment Board lifted its stake in shares of Hologic by 72.6% during the 1st quarter. Canada Pension Plan Investment Board now owns 453,913 shares of the medical equipment provider’s stock worth $35,387,000 after purchasing an additional 190,881 shares during the last quarter. Finally, 1832 Asset Management L.P. lifted its stake in shares of Hologic by 6.2% during the 1st quarter. 1832 Asset Management L.P. now owns 27,417 shares of the medical equipment provider’s stock worth $2,137,000 after purchasing an additional 1,597 shares during the last quarter. 94.73% of the stock is owned by hedge funds and other institutional investors.

Hologic Trading Up 0.8 %

Hologic stock opened at $78.68 on Friday. The company has a market capitalization of $18.28 billion, a price-to-earnings ratio of 23.63, a PEG ratio of 2.48 and a beta of 0.98. The company’s fifty day moving average price is $80.49 and its two-hundred day moving average price is $78.30. Hologic, Inc. has a one year low of $67.59 and a one year high of $84.67. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.69 and a quick ratio of 3.03.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The business had revenue of $987.90 million during the quarter, compared to analyst estimates of $978.25 million. During the same quarter last year, the business posted $0.89 earnings per share. Hologic’s revenue for the quarter was up 4.5% compared to the same quarter last year. On average, analysts forecast that Hologic, Inc. will post 4.27 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

HOLX has been the topic of a number of research reports. UBS Group increased their price objective on Hologic from $84.00 to $90.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Leerink Partners reduced their price objective on Hologic from $95.00 to $90.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. Mizuho dropped their price objective on Hologic from $90.00 to $87.00 and set an “outperform” rating for the company in a research note on Tuesday, November 5th. Evercore ISI boosted their target price on Hologic from $78.00 to $82.00 and gave the stock an “in-line” rating in a research note on Tuesday, October 1st. Finally, Citigroup downgraded Hologic from a “buy” rating to a “neutral” rating and reduced their target price for the company from $95.00 to $85.00 in a report on Tuesday, October 1st. Four analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, Hologic presently has a consensus rating of “Moderate Buy” and an average target price of $89.91.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.